PMID- 35678328
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20220930
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 151
IP  - 10
DP  - 2022 Nov 15
TI  - Early onset metastatic colorectal cancer in patients receiving panitumumab-based 
      upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
PG  - 1760-1769
LID - 10.1002/ijc.34156 [doi]
AB  - Anti-EGFRs plus doublet chemotherapy is considered the optimal upfront option for 
      RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). Early-onset 
      (EO) mCRC has an increasing incidence and its prognostic/predictive role and 
      management is debatable. We performed a post hoc analysis of Valentino study, 
      that randomized RAS wild-type mCRC patients to two panitumumab-based maintenance 
      regimens after FOLFOX/panitumumab induction. We assessed the safety and efficacy 
      outcomes in patients stratified for age (<50/>/=50 years old). We assessed 
      progression-free survival (PFS), overall survival (OS), response rate (ORR), rate 
      of treatment-related and panitumumab-related adverse events (AEs) and quality of 
      life (QoL). In 229 patients enrolled, 35 (15%) had EO mCRC, with a higher rate of 
      female sex (P = .020) and lower rate of primary tumor resection (P = .001). 
      Median PFS and OS were 10.9 vs 10.8 months (P = .593) and 28.1 vs 27.5 months 
      (P = .865) in patients <50 and >/=50 years old, respectively, with no significant 
      impact of maintenance arm. ORR and disease control rate were 74% vs 65% 
      (P = .337) and 97% vs 81% (P = .013) in patients <50 or >/=50 years old. In younger 
      patients, a trend for increased chemotherapy-related AEs (peculiarly anemia) was 
      shown, while significantly decreased EGFR-related hypomagnesemia and increased 
      skin rash were reported. No significant differences in treatment intensity or QoL 
      were observed. In patients with EO mCRC and RAS wild-type status, we found no 
      differences in terms of survival outcomes based on age when selecting maintenance 
      strategies. Management of treatment-related AEs should consider the differential 
      toxicity profile of age and sex.
CI  - (c) 2022 UICC.
FAU - Raimondi, Alessandra
AU  - Raimondi A
AUID- ORCID: 0000-0002-8999-2899
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Randon, Giovanni
AU  - Randon G
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Prisciandaro, Michele
AU  - Prisciandaro M
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
AD  - Oncology and Hemato-oncology Department, University of Milan, Milan, Italy.
FAU - Pagani, Filippo
AU  - Pagani F
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Lonardi, Sara
AU  - Lonardi S
AD  - Department of Oncology, Veneto Institute of Oncology IRCCS, Padua, Italy.
FAU - Antoniotti, Carlotta
AU  - Antoniotti C
AD  - Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
FAU - Bozzarelli, Silvia
AU  - Bozzarelli S
AD  - Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas 
      Research Hospital, Rozzano, Italy.
FAU - Sartore-Bianchi, Andrea
AU  - Sartore-Bianchi A
AD  - Oncology and Hemato-oncology Department, University of Milan, Milan, Italy.
AD  - Division of Oncology, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
FAU - Tampellini, Marco
AU  - Tampellini M
AD  - Department of Oncology, AOU San Luigi di Orbassano, University of Torino, 
      Orbassano, Italy.
FAU - Fanchini, Laura
AU  - Fanchini L
AD  - SSD ColoRectal Cancer Unit-Dipartimento di Oncologia, AOU Citta della Salute e 
      della Scienza di Torino, Torino, Italy.
FAU - Murialdo, Roberto
AU  - Murialdo R
AD  - Department of Internal Medicine, University of Genoa and IRCCS AOU San 
      Martino-IST, Genoa, Italy.
FAU - Clavarezza, Matteo
AU  - Clavarezza M
AD  - Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
FAU - Zaniboni, Alberto
AU  - Zaniboni A
AD  - Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
FAU - Berenato, Rosa
AU  - Berenato R
AD  - Medical Oncology Unit, AO Papardo, Messina, Italy.
FAU - Ratti, Margherita
AU  - Ratti M
AD  - Medical Oncology Unit, ASST Ospedale di Cremona, Cremona, Italy.
FAU - Petrelli, Fausto
AU  - Petrelli F
AD  - Medical Oncology Unit, Oncology Department, ASST Bergamo Ovest, Treviglio, Italy.
FAU - Antonuzzo, Lorenzo
AU  - Antonuzzo L
AD  - Clinical Oncology Unit, AOU Careggi, Florence, Italy.
AD  - Department of Experimental and Clinical Medicine, University of Florence, 
      Florence, Italy.
FAU - Giordano, Monica
AU  - Giordano M
AD  - Medical Oncology Unit, Azienda Socio Sanitaria Territoriale Lariana, Como, Italy.
FAU - Rossi, Alessandro
AU  - Rossi A
AD  - Department of Clinical and Molecular Medicine, Oncology Unit, "La Sapienza" 
      University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, Italy.
FAU - Di Bartolomeo, Maria
AU  - Di Bartolomeo M
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Di Maio, Massimo
AU  - Di Maio M
AD  - Department of Oncology, University of Turin, Division of Medical Oncology, Ordine 
      Mauriziano Hospital, Turin, Italy.
FAU - Pietrantonio, Filippo
AU  - Pietrantonio F
AUID- ORCID: 0000-0002-8530-8420
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Morano, Federica
AU  - Morano F
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220623
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 6A901E312A (Panitumumab)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Colorectal Neoplasms/drug therapy/genetics
MH  - Female
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Panitumumab/therapeutic use
MH  - Prognosis
MH  - Proto-Oncogene Proteins B-raf
MH  - *Quality of Life
OTO - NOTNLM
OT  - EGFR inhibitor
OT  - age
OT  - colorectal cancer
OT  - early-onset colorectal cancer
OT  - metastasis
EDAT- 2022/06/10 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/06/09 07:12
PHST- 2022/05/24 00:00 [revised]
PHST- 2022/03/28 00:00 [received]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2022/06/10 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/06/09 07:12 [entrez]
AID - 10.1002/ijc.34156 [doi]
PST - ppublish
SO  - Int J Cancer. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 
      Jun 23.